{"id":"elbasvir-grazoprevir-fixed-dose-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:57:37.025280","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Elbasvir inhibits the HCV NS5A protein, which is essential for viral RNA replication and virion assembly. Grazoprevir inhibits the HCV NS3/4A serine protease, which is required for processing of the HCV polyprotein. Together, this dual mechanism prevents HCV replication and allows viral clearance.","oneSentence":"Elbasvir and grazoprevir are hepatitis C virus (HCV) NS5A inhibitor and NS3/4A protease inhibitor, respectively, that work together to block viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:15.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype 1, 4, 5, 6)"}]},"_fixedFields":["pubmed(5)"],"trialDetails":[{"nctId":"NCT04048850","phase":"","title":"Zepatier in Patients with Substance Use","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2019-09-20","conditions":"Hepatitis C, Hiv, Coinfection, HIV","enrollment":25},{"nctId":"NCT03496233","phase":"PHASE3","title":"Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo","startDate":"2018-09-19","conditions":"Chronic HCV Hepatitis","enrollment":75},{"nctId":"NCT03144440","phase":"","title":"Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2016-12-13","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT02105701","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Hepatitis C Infection","enrollment":420},{"nctId":"NCT02105662","phase":"PHASE3","title":"An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-03","conditions":"Chronic Hepatitis C","enrollment":218},{"nctId":"NCT03578640","phase":"PHASE3","title":"Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4","status":"COMPLETED","sponsor":"King Fahad Medical City","startDate":"2018-07-01","conditions":"Hepatitis C, Chronic","enrollment":30},{"nctId":"NCT02973503","phase":"PHASE3","title":"Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2017-01-11","conditions":"Chronic HCV Infection","enrollment":117},{"nctId":"NCT02945150","phase":"PHASE4","title":"Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-02-01","conditions":"Renal Failure","enrollment":8},{"nctId":"NCT03420300","phase":"PHASE4","title":"EBR/GZR for HCV-1b Patients Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-06-05","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT02886624","phase":"PHASE2","title":"Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2017-05-31","conditions":"Acute Hepatitis C, HIV","enrollment":30},{"nctId":"NCT02601573","phase":"PHASE2","title":"Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-05","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT02115321","phase":"PHASE2, PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-09","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT03186365","phase":"PHASE3","title":"8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2017-06-12","conditions":"Hepatitis C, Chronic","enrollment":82},{"nctId":"NCT03026023","phase":"PHASE4","title":"Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant","status":"WITHDRAWN","sponsor":"Raymond T. Chung, MD","startDate":"2018-08-01","conditions":"Cardiac Transplant Disorder, Hepatitis C","enrollment":""},{"nctId":"NCT03098121","phase":"PHASE4","title":"Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection","status":"COMPLETED","sponsor":"Taoyuan General Hospital","startDate":"2017-10-20","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT02105467","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Chronic Hepatitis C Virus","enrollment":421},{"nctId":"NCT02781649","phase":"PHASE4","title":"Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2016-07-20","conditions":"End-Stage Renal Disease, Hepatitis C","enrollment":10},{"nctId":"NCT03585101","phase":"PHASE4","title":"A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2018-08","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03143998","phase":"PHASE4","title":"Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-12","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03222167","phase":"PHASE3","title":"Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b","status":"UNKNOWN","sponsor":"Institute Of Cardiology & Internal Diseases, Kazakhstan","startDate":"2017-10","conditions":"Chronic Hepatitis C Genotype 1B, Metabolic Syndrome, Fibrosis, Liver","enrollment":60},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Elbasvir/Grazoprevir Fixed Dose Combination","genericName":"Elbasvir/Grazoprevir Fixed Dose Combination","companyName":"University Hospital, Clermont-Ferrand","companyId":"university-hospital-clermont-ferrand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Elbasvir and grazoprevir are hepatitis C virus (HCV) NS5A inhibitor and NS3/4A protease inhibitor, respectively, that work together to block viral replication. Used for Chronic hepatitis C virus infection (genotype 1, 4, 5, 6).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}